Following a lackluster first quarter for small biotechs, the pharmaceutical industry is witnessing a surge in tuck-in deals. Ventyx, with upcoming Phase II Parkinson’s disease results, struck a deal with Sanofi granting the pharma right of first negotiation (ROFN) on an acquisition. This agreement, driven by a shared interest in novel central nervous system therapies, […]
Tag: Sanofi
Sanofi Acquires Blueprint for Immunology Advancements
Sanofi’s acquisition of Blueprint Medicines for up to $9.5B marks a significant move in the realm of immunology. The FDA’s approval of Ayvakit in 2020 for a rare gastrointestinal tumor, along with its subsequent clearance as a treatment for systemic mastocytosis, showcases the medicine’s potential in addressing challenging medical conditions involving mast cell accumulation and […]
CDSCO Approves Fabrazyme Label Update for Sanofi EMA Submission
The Central Drugs Standard Control Organization (CDSCO) panel has granted approval for an update to the Fabrazyme label, directing Sanofi to submit the nod from the European Medicines Agency (EMA). This decision marks a significant step in ensuring compliance with regulatory requirements and aligning the product information with current standards. Fabrazyme, a medication used in […]
Regeneron’s Strategic Licensing for Dual GLP-1/GIP Receptor Agonist
Regeneron Pharmaceuticals, Inc. expands its clinical-stage obesity portfolio through a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited. This agreement grants Regeneron exclusive rights outside of China for HS-20094, a novel dual GLP-1/GIP receptor agonist. The In-Licensing Transaction involves potential benefits, regulatory considerations, and anticipated clinical development pathways. Regeneron aims to address obesity-related comorbidities […]
SK Bioscience Wins Patent Battle with Pfizer on Pneumococcal Vaccine
Following a recent patent lawsuit, SK Bioscience emerges victorious over Pfizer in the realm of pneumococcal vaccines. Looking ahead, SK Bioscience is poised to strengthen its position in the global market. In 2027, the company will introduce SKYPneumo for domestic manufacturing and sales. Moreover, a collaboration with Sanofi has led to the development of a […]
